Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Line Items]
Impairment loss	$ 66,900,000	$ 3,300,000	$ 0
Accumulated deficit	468,121,000	393,717,000
Cash and cash equivalents and short-term investments	216,500,000
Short-term investments, allowance for expected credit losses	0	0
Deposits	$ 900,000	700,000
Weighted Average Remaining Amortization Period (Years)	6 years 10 months 24 days
Impairment of indefinite-lived intangible assets	$ 0	0	0
Impairment of goodwill	0	0	0
Total revenue	361,051,000	296,536,000	219,514,000
Accounts receivable	40,378,000	44,021,000
Prepaids and Other Current Assets | French | Research Tax Credit Carryforward
Accounting Policies [Line Items]
Tax credit carryforward	4,700,000
Other Assets | French | Research Tax Credit Carryforward
Accounting Policies [Line Items]
Tax credit carryforward	4,600,000
Other Testing Revenue
Accounting Policies [Line Items]
Total revenue	7,800,000	3,100,000	1,100,000
Biopharmaceutical and other revenue
Accounting Policies [Line Items]
Total revenue	18,921,000	33,360,000	$ 19,868,000
Accounts receivable	6,000,000	9,300,000
Deferred revenue	$ 2,000,000	2,600,000
Minimum
Accounting Policies [Line Items]
Property and equipment useful lives	3 years
Weighted Average Remaining Amortization Period (Years)	4 years
Maximum
Accounting Policies [Line Items]
Property and equipment useful lives	5 years
Weighted Average Remaining Amortization Period (Years)	15 years
Impairment Of Long-Term Assets
Accounting Policies [Line Items]
Impairment loss		$ 3,300,000